ChartMill assigns a Buy % Consensus number of 85% to NAUT. The Buy consensus is the weighted average rating of the current analysts ratings.
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2024-12-05 | Goldman Sachs | Downgrade | Neutral -> Sell |
| 2024-06-27 | Guggenheim | Initiate | Buy |
| 2023-08-03 | Morgan Stanley | Reiterate | Equal-Weight -> Equal-Weight |
| 2022-08-03 | Goldman Sachs | Maintains | Neutral |
| 2022-08-03 | Morgan Stanley | Maintains | Equal-Weight |
| 2022-07-14 | Goldman Sachs | Maintains | Neutral |
| 2022-04-13 | Goldman Sachs | Maintains | Neutral |
| 2022-01-06 | Morgan Stanley | Initiate | Equal-Weight |
| 2021-11-02 | Cowen & Co. | Initiate | Outperform |
| 2021-08-04 | Goldman Sachs | Initiate | Neutral |
| 2021-07-13 | Jefferies | Initiate | Buy |
8 analysts have analysed NAUT and the average price target is 2.55 USD. This implies a price increase of 25.62% is expected in the next year compared to the current price of 2.03.
The consensus rating for NAUTILUS BIOTECHNOLOGY INC (NAUT) is 85 / 100 . This indicates that analysts generally have a positive outlook on the stock.
The number of analysts covering NAUTILUS BIOTECHNOLOGY INC (NAUT) is 8.